In the sixth Preview relating to the annual meeting at #AACR17, we take a closer look at an immuno-oncology topic that we are likely to see and hear more about over the next couple of years.

Indeed, I’ve followed some cancer conferences where it wasn’t even mentioned, much to my surprise. It should be, it’s likely going to be both needed and receive a lot of attention over the next few years.

What we need is a bridge for greater success.  What does that look like though and how do we go about achieving it?

Subscribers can log-in to learn more or you can sign up via the blue box below…

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR, COMMUNICATIONS OR MEDIA (that includes JOURNALISTS & WRITERS), you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you are in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first. Please note that we do not collect or remit any sales taxes. The purchaser is solely responsible for ensuring compliance with tax laws where they reside or use our content and for the reporting and payment, at their expense, of any use tax or other taxes that may be due as a result of this purchase. An accountant, tax advisor or lawyer should be consulted for advice on any obligation.